
    
      Nimotuzumab is a humanized monoclonal antibody against epidermal growth factor receptor
      (EGFR). Clinical trials are ongoing globally to evaluate Nimotuzumab in different
      indications. Nimotuzumab has been approved to treat squamous cell carcinoma of head and neck
      (SCCHN), glioma and nasopharyngeal carcinoma in different countries.The clinical phase Ⅲ
      trial designed to assess overall survival（OS）of the combination of Nimotuzumab administered
      concurrently with Gemcitabine in patients with RAS wild type of locally advanced or
      metastatic pancreatic cancer.Secondary objectives include time to
      progression（TTP）,progression-free survival（PFS）,Objective Response Rate（ORR）,Disease Control
      Rate（DCR）,Clinical Benefit Response（CBR）and safety.
    
  